Arcturus Therapeutics

Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. It is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The firm's products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arcturus Therapeutics reports robust earnings and advances in mRNA pipeline

Arcturus Therapeutics delivered strong financial results and showcased progress across key strategic areas
The company's collaborations, advancements in RNA technology, and clinical trial milestones position it for future success
While facing competition and challenges, Arcturus has opportunities to leverage its strengths and drive growth in the mRNA space

Arcturus reports strong Q1 earnings, advances COVID vaccine development

Arcturus Therapeutics demonstrated robust financial performance, progress in COVID-19 vaccine development, and advancements in mRNA therapeutics.
While facing challenges in drug safety and regulatory approvals, the company is well-positioned to capitalize on opportunities for expansion and innovation.
Strategic collaborations and a strong cash position enhance Arcturus' competitive edge and potential for sustained growth in the biopharmaceutical sector.

Arcturus Therapeutics reports Q2 results, advances key programs with CSL

Arcturus Therapeutics showcased financial resilience with a strong cash position and promising program advancements in Q2 2023.
While facing challenges such as high operating expenses and uncertainties in clinical trials, the company is leveraging opportunities for market expansion and program advancement.
Collaboration with CSL and progress on key programs like ARCT-154 and ARCT-810 position Arcturus for continued growth and innovation in the biopharmaceutical space.
Investors can look forward to data releases, program updates, and potential market expansions as Arcturus navigates financial challenges and capitalizes on growth opportunities.

Arcturus Therapeutics excels in Q3 with promising pipeline advancements

Arcturus Therapeutics demonstrated strong financial performance, operational efficiency, and clinical progress in key pipeline candidates, positioning the company for future growth and success.
The company's technological strengths, diverse pipeline, and strategic partnerships underscore its innovation and commitment to addressing unmet medical needs, enhancing market competitiveness.
While facing challenges in regulatory approvals and study outcomes, Arcturus has opportunities to expand its product portfolio, leverage mRNA technology advantages, and drive market growth through strategic planning.
Overall, Arcturus' Q3 earnings call highlights a balanced outlook of financial stability, clinical advancements, and strategic opportunities, signaling a positive trajectory for the company's future.

Arcturus Therapeutics reports mixed financials but strong vaccine pipeline

Arcturus Therapeutics faces financial challenges with expenses exceeding revenues, but maintains a stable cash runway and strong pipeline of vaccine programs
The company's focus on vaccine development for various diseases and mRNA therapeutics showcases promising strengths and diversification in its product offerings
Opportunities in the Japanese market, upcoming Phase II study results, and operational advancements present avenues for growth and value creation for Arcturus

Arcturus reports Q1 results, eyes growth through clinical progress

Arcturus Therapeutics reported mixed financial results in Q1 2024 but remains well-positioned with strong cash reserves and ongoing clinical advancements.
Challenges include managing expenses, revenue variability, and timing uncertainties in future guidance tied to Kostaive revenues.
However, opportunities lie in positive trial outcomes, potential milestone payments, and strategic alignment with global health initiatives.
Overall, Arcturus shows promise in its financial stability, clinical progress, and strategic positioning for future growth and innovation.

Arcturus Therapeutics excels in Q2 2024, poised for mRNA innovation

Arcturus Therapeutics demonstrated strong financial performance and progress in key programs, supported by a solid cash position and strategic collaborations.
While facing challenges such as cost management and regulatory complexities, the company is well-positioned to leverage opportunities in mRNA therapeutics and vaccine development.
Overall, Arcturus shows promise in advancing its pipeline and capturing growth opportunities in the evolving biopharmaceutical landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Catalent

SAN DIEGO and SOMERSET, N.J., May  04, 2020  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus”, “the Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to protect against the SARS-CoV-2 coronavirus.

Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine

SAN DIEGO, April  16, 2020  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced the pricing of an underwritten public offering of 4,117,650 shares of its common stock at a public offering price of $17.00 per share. The gross proceeds of the offering to the Company are expected to be approximately $70 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwriters a thirty-day option to purchase up to an additional 617,647 shares of common stock at the public offering price, less underwriting discounts and commissions.

Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock

Clinical Plan Includes Healthy Volunteers in New Zealand and  OTC-Deficient Patients Across Several Sites in United States

Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency

GMP-Manufactured Batch to be Delivered in June 2020   Human Dosing Expected to Begin in Summer 2020

Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine

Data will help Arcturus learn more quickly about LUNAR-COV19 efficacy and safety profile Data will help Arcturus learn more quickly about LUNAR-COV19 efficacy and safety profile

Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System

Aurinia Pharmaceuticals

Chemocentryx

Kadmon Hlds

Novavax

Nevro

Thermo Fisher Scientific

Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.

7 “Perfect 10” Healthcare Stocks to Buy Now

Arcturus Therapeutics Holdings, Inc. (ARCT) CEO Joseph Payne on Q4 2019 Results - Earnings Call Transcript

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -55.10% and -34.04%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Reports Q4 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcturus Therapeutics (ARCT) Expected to Beat Earnings Estimates: Should You Buy?

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock jumped on Wednesday after the company announced that it would be joining the fight against the latest coronavirus.

What Arcturus Therapeutics Brings to the Fight Against the Coronavirus

Collaboration seeks to conduct pre-clinical testing followed by first-in-human clinical trials Collaboration seeks to conduct pre-clinical testing followed by first-in-human clinical trials

Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR Technology™

SAN DIEGO, Jan.  08, 2020  (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced the appointment of Steve Hughes, M.D., as Chief Development Officer, effective January 2, 2020. Dr. Hughes brings over twenty years of clinical development experience in the fields of rare diseases, cardiovascular disease, and oncology. His most recent successes include RNA therapeutic approvals at Ionis Pharmaceuticals for the treatment of rare diseases including transthyretin-mediated amyloidosis (TEGSEDI®), familial chylomicronemia syndrome (WAYLIVRA®) and spinal muscular atrophy (SPINRAZA®).  

Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer

SAN DIEGO, Nov.  07, 2019  (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT, the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that the Company is expanding its platform to include STARR (Self-Transcribing And Replicating RNA) technology™ for human and animal health vaccine applications.

Arcturus Therapeutics Expands Platform with STARR Technology™

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Arcturus Therapeutics (ARCT) Report Negative Q3 Earnings? What You Should Know

Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Arcturus Therapeutics (ARCT) Upgraded to Buy: Here's What You Should Know

SAN DIEGO, Oct.  02, 2019  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Joseph Payne, Chief Executive Officer, will provide a corporate overview at three upcoming investor conferences: the Chardan Capital Markets 3rd Annual Genetic Medicines Conference, October 7-8 in New York City; the Stifel Healthcare Conference 2019, November 19-20 in New York City; and, the LD Micro Annual Main Event, December 10-12th in Bel Aire, California.

Arcturus Therapeutics to Present at Three Upcoming Investor Conferences

SAN DIEGO, Sept.  23, 2019  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Professor Edward W. Holmes, M.D., joined the Board of Directors and Andy Sassine was re-appointed effective September 17, 2019.  

Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D.

President and CEO of Arcturus Therapeutics Holdings Inc (30-Year Financial, Insider Trades) Joseph E Payne (insider trades) bought 5,000 shares of ARCT on 08/29/2019 at an average price of $11.22 a share.

Arcturus Therapeutics Holdings Inc (ARCT) President and CEO Joseph E Payne Bought $56,100 of Shares

SAN DIEGO, Aug.  26, 2019  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Joseph Payne, Chief Executive Officer, will present a corporate update at the H.C. Wainwright 21st Annual Global Investment Conference, and the Ladenburg Thalmann 2019 Healthcare Conference.

Arcturus Therapeutics To Present at Two Investor Conferences in September

CFO of Arcturus Therapeutics Holdings Inc (30-Year Financial, Insider Trades) Andy Sassine (insider trades) bought 10,000 shares of ARCT on 08/23/2019 at an average price of $10.9 a share.

Arcturus Therapeutics Holdings Inc (ARCT) CFO Andy Sassine Bought $109,000 of Shares

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2019 Results - Earnings Call Transcript

CACI

Barrick Gold

JD.com

Victory Capital Holdings

In line with better-than-expected earnings reports, five companies are set to beat earnings estimates next week.

5 High-Flying Stocks Set to Beat on Earnings in Q2 Next Week

The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.

Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status

Ultragenyx Pharmaceutical

Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.

News for Arcturus Therapeutics Stock (ARCT)